Publications by authors named "Xiu-fang Xing"
Article Synopsis
- The study aimed to assess the dose-dependent effects of tranexamic acid (TXA) on fibrinolysis in adult patients undergoing cardiac surgery.
- Thirty patients were randomly assigned to placebo, low-dose, and high-dose TXA groups, with various fibrinolysis markers measured before and after surgery.
- Results showed that both TXA doses reduced D-Dimer levels and influenced other fibrinolysis parameters, with significant differences observed predominantly in PAI-1 and TAFI concentrations among the study groups.
Background: Postherpetic neuralgia (PHN) is the most common and refractory complication of herpes zoster (HZ). Aggressive treatment of acute pain in HZ has the potential to prevent the development of PHN, but the preventive efficacy of supplemental therapy commonly used in clinical practice is controversial.
Objectives: Our aim is to examine the efficacy of supplemental therapy in preventing PHN.
Background: Stroke is a devastating and potentially preventable complication of cardiac surgery. Tranexamic acid (TXA) is a commonly antifibrinolytic agent in cardiac surgeries with cardiopulmonary bypass (CPB), however, there is concern that it might increase incidence of stroke after cardiac surgery. In this retrospective study, we investigated whether TXA usage could increase postoperative stroke in cardiac surgery.
View Article and Find Full Text PDF[Determination of gentiopicroside in different morphological types of cultivated Gentiana manshurica population].
Zhongguo Zhong Yao Za Zhi
September 2004
Objective: To study the correlation between morphological variation and gentiopicroside content in cultivated Gentiana manshurica roots and to investigate the feasibility of breeding new varieties of high effective constituent content.
Method: Gentiopicroside was determined in 5 morphological types of cultivated G. manshurica roots by HPLC, which are normal (or wild) type, white-flowered type, thick-rooted type, broad-leaved type I and broad-leaved type II.